The Complete Cellular Energy Peptide Protocol

Your mitochondria are not broken. They are starved, overloaded, and running on a membrane that has been slowly degrading for decades, and the question is not whether you can support them but in what order the interventions actually matter.

Start with the full picture before zooming into any single compound.

Your cells make energy through a chain of events that begins with raw materials coming in through your diet, moves through a series of enzymatic reactions that require cofactors like NAD+ and CoQ10 and magnesium, and ends with ATP being produced at something called the electron transport chain, which is a series of protein complexes embedded in the inner membrane of the mitochondria where electrons are passed down the line to drive the production of usable cellular energy. When that membrane is damaged, or when the raw materials are missing, or when the cells doing all of this are senescent and no longer functioning properly, every step downstream degrades. That is the system. The protocol in the video is just working backward through it, fixing each bottleneck in order.

The foundation comes first because nothing works without it.

Creatine at 5 grams per day is not just for muscle. It maintains the phosphocreatine pool that your cells use to rapidly regenerate ATP between production cycles, and without it you are starting every energy demand from a deficit. CoQ10 is an electron carrier inside that transport chain and a membrane-bound antioxidant. Magnesium is a cofactor for over 300 enzymatic reactions, including several inside the mitochondria. Vitamin D3 with K2 regulates gene expression tied to mitochondrial biogenesis, meaning how many new mitochondria your cells are making. Without these, adding peptides on top is like trying to optimize a factory that does not have electricity running to the building.

NAD+ is where the protocol starts doing something the foundation cannot.

NAD+ is a molecule that functions as an electron carrier in the same energy production chain, and it also feeds a class of enzymes called sirtuins and PARPs that regulate mitochondrial health, DNA repair, and cellular stress response. The problem is that NAD+ levels drop significantly with age, and they also drop faster if you have inflammation, metabolic dysfunction, or DNA damage consuming them faster than your cells can produce them. The enzyme responsible for making NAD+ from scratch inside your cells is something called NAMPT, and if you suppress it chronically by flooding the system with precursors or injectable NAD+ without cycling, your body downregulates its own production. That is why the 8 to 12 weeks on, 4 to 8 weeks off structure exists, and it is also why someone in their late 30s with intact NAMPT activity may get equal results from oral NMN or niacin without needing injections.

Past 45 or 50, there is a problem that NAD+ cannot fix on its own.

Senescent cells are cells that have stopped dividing but have not been cleared by the body, and they sit inside your tissues releasing a toxic mix of inflammatory signals called the senescence-associated secretory phenotype. That inflammation degrades the mitochondria in surrounding cells, drives oxidative stress, and consumes NAD+ faster than you can replace it. A compound called FOXO4-DRI works by targeting the mechanism that senescent cells use to resist their own programmed death. FOXO4 is a protein that sequesters p53, the protein responsible for triggering apoptosis, and it holds it in the nucleus of senescent cells specifically to prevent them from dying. FOXO4-DRI is a modified peptide that disrupts that interaction and allows p53 to do its job. In the 2017 Cell study by de Keizer and colleagues, FOXO4-DRI showed 11.73-fold selectivity for senescent cells over healthy cells, which means the mechanism is specific enough to be useful even though the human data is still preclinical. You clear that burden first, because if you do not, everything you add afterward is fighting against a tide of chronic inflammation that is actively dismantling the machinery you are trying to repair.

SS-31 is the compound that addresses the membrane itself.

The inner mitochondrial membrane is where ATP synthesis physically happens, and it requires a very specific phospholipid called cardiolipin to maintain its structure, to hold the electron transport chain complexes in proper alignment, and to support something called the membrane potential, which is the electrochemical gradient that drives ATP production the way water pressure drives a turbine. Cardiolipin oxidizes with age and with oxidative stress, and when it oxidizes, the complexes drift apart, electron leakage increases, and the same amount of fuel produces less energy while generating more reactive oxygen species. SS-31, also known as elamipretide, binds directly to cardiolipin and concentrates in the inner membrane, reducing that electron leakage by 40 to 60 percent in the research from Szeto's lab published in the British Journal of Pharmacology. The TAZ-POWER trial, which ran three years in patients with a genetic cardiolipin deficiency called Barth syndrome, showed a 96-meter improvement on the six-minute walk test alongside a 45 percent improvement in leg strength and cardiac function. That is a population with severe baseline dysfunction, but the mechanism of membrane repair is the same one that degrades more slowly in everyone with age and oxidative stress.

MOTS-c completes the pair because it works upstream.

MOTS-c is a peptide encoded in the mitochondrial genome itself, meaning it is a signal the mitochondria produce to communicate with the rest of the cell, and its primary job is activating something called AMPK, which is the cell's master energy sensor and one of the main regulators of how efficiently your cells use fuel. When AMPK is activated, cells shift toward burning fatty acids and glucose more efficiently, reduce unnecessary energy expenditure, and upregulate their own antioxidant defenses. A 2026 study published in Free Radical Biology and Medicine by Gudiksen and colleagues showed that MOTS-c improves intrinsic mitochondrial efficiency independent of changes in mitochondrial volume, meaning the mitochondria you already have are running better, not just multiplying. The reason SS-31 and MOTS-c stack cleanly is that one is repairing the physical structure of the membrane and the other is improving the signaling that governs how that structure is used. They are not overlapping. They are working on different parts of the same machine.

The conditional tier exists because not every dysfunction is universal.

5-Amino-1MQ blocks an enzyme called NNMT, which is expressed heavily in adipose tissue and consumes SAM-e and NAD+ precursors in a way that contributes to metabolic dysfunction. In a mouse study by Nkandeu and colleagues, NNMT inhibition produced a 35 percent reduction in body mass alongside metabolic improvements. If you are lean and metabolically healthy, there is no excess NNMT activity to block, so the compound has nothing meaningful to correct. Methylene blue can directly accept electrons in the transport chain as an alternative electron carrier, which is useful when the chain is damaged and electrons are leaking out, but it interacts with the serotonin system and creates hemolytic risk in people with G6PD deficiency, which means it requires testing before use and is incompatible with SSRIs. Injectable L-carnitine exists in this tier because oral carnitine has poor bioavailability and the injectable form reliably gets carnitine into circulation where it can shuttle fatty acids into the mitochondria for beta-oxidation.

What the ordering of this protocol is actually telling you is that the infrastructure has to come before the optimization.

You cannot repair a membrane that is still being bombarded by inflammation from senescent cells. You cannot get full value from NAD+ support if the electron transport chain it feeds is leaking electrons through oxidized cardiolipin. You cannot optimize AMPK signaling if the mitochondria doing the work are structurally compromised. Each tier is not just an add-on. It is a prerequisite for the one above it to matter.

The insight is this: most people approach mitochondrial health by adding things and hoping something helps, and this protocol is structured in the opposite direction, starting with what is blocking the system from working at all before adding anything that depends on the system working to be effective.

---

References

1. Thompson WR et al. TAZ-POWER trial. Genetics in Medicine. 2024;26(7):101133 — SS-31 (elamipretide) +96m on 6MWT, +45% leg strength/cardiac function over 3 years
2. Szeto HH. Mitochondria-targeted cytoprotective peptides. British Journal of Pharmacology. 2014;171:2029-2050 — SS-31 mechanism, cardiolipin binding, 40-60% ROS reduction
3. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015 — MOTS-c AMPK activation, insulin sensitivity
4. Gudiksen A et al. Free Radical Biology and Medicine. 2026;246:682-696 — MOTS-c improves intrinsic mitochondrial efficiency
5. de Keizer et al. Targeted apoptosis of senescent cells. Cell. 2017 — FOXO4-DRI senolytic mechanism, 11.73-fold selectivity
6. Khavinson et al. Epithalon telomerase activation research — limited human + animal data
7. Nkandeu et al. 5-Amino-1MQ mouse study — 35% body mass reduction, NNMT inhibition in adipose tissue

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness